Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
Addex Therapeutics Ltd - American Depositary Shares (ADXN)
Company Research
Source: GlobeNewswire
Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today publication of data in Molecular Psychiatry1 demonstrating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators (NAM) could be transformative in the treatment of anxiety and fear-related disorders, such as post-traumatic stress disorder (PTSD). In the study, scientists from the Center for Psychiatric Neurosciences (CNP, CHUV/UNIL) in Lausanne, Switzerland, evaluated the effects of ADX71743, a highly selective mGlu7 NAM, in established models of fear learning and memory. The results demonstrated that mGlu7 modulation can selectively interfere with the reconsolidation of fear memories, the process in the brain
Show less
Read more
Impact Snapshot
Event Time:
ADXN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADXN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADXN alerts
High impacting Addex Therapeutics Ltd - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADXN
News
- Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment [Yahoo! Finance]Yahoo! Finance
- Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia [Yahoo! Finance]Yahoo! Finance
- Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for SchizophreniaGlobeNewswire
- Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.GlobeNewswire
- Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]Yahoo! Finance
ADXN
Sec Filings
- 2/3/26 - Form 6-K
- 1/7/26 - Form 6-K
- 12/10/25 - Form 6-K
- ADXN's page on the SEC website